BIOS

59. Future of ADCs w/ David Epstein - CEO @ Seagen

Jun 12, 2023
David Epstein, the CEO of Seagen with over 30 years in drug development, shares his insights on antibody-drug conjugates (ADCs) and their transformative potential in cancer therapy. He discusses the journey of innovation in pharmaceuticals, contrasting big pharma with startups. The conversation dives into the recent advancements in ADCs, their revolutionary impact on targeted treatment, and the collaborative efforts driving progress in oncology. Epstein also emphasizes the exciting future possibilities when combining ADCs with immunotherapy.
Ask episode
Chapters
Transcript
Episode notes